Dren Bio and Novartis Pharma have entered a strategic collaboration focused on the discovery and development of therapeutic bispecific antibodies for cancer. Under the terms of the agreement, Dren Bio will receive a total upfront consideration of $150 million from Novartis, which includes a $25 million equity investment in the company. Dren Bio is also […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!